AstraZeneca has entered an exclusive licence agreement with Alteogen involving the latter’s ALT-B4 platform technology.

The use of AI in drug discovery and development has been recognised, explored, and implemented throughout the last decade, with a notable acceleration in recent years.

Experts at the 2025 Clinical Trial Supply New England conference will discuss strategies for optimising clinical supply ...

Latigo has secured $150m in a Series funding round, which will be used to further the development of its Nav1.8 inhibitors.

The two simultaneous Incyte trials in HS saw more than 40% of patients on povorcitinib achieving a clinical response.

Taiho Pharmaceutical has agreed to acquire Swiss-based antibody-drug-conjugate (ADC) specialist Araris Biotech for up to ...

While China has become a key country for global clinical trials, navigating regulatory complexities and ensuring data ...

Azurity Pharmaceuticals has acquired Covis Group from existing investors, making the latter a wholly owned subsidiary.

The EC has granted expanded approval to BMS' Breyanzi, to treat adults with relapsed or refractory follicular lymphoma (FL).

Telix states its automated and high-throughput generator can produce sufficient lead-212 elution for up to 60 clinical doses, ...

WuXi XDC Cayman has signed a memorandum of understanding (MoU) with South Korea-based AbTis to advance next-generation ADCs.

The deal comes after a challenging few years for 2seventy bio, which had divested research programmes in recent years.